Royal Bank Of Canada Reata Pharmaceuticals Inc Transaction History

Royal Bank Of Canada

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$79.22 - $105.37 $119,701 - $159,214	1,511 Added 77.45%	3,462 $352,000
Q1 2023 May 15, 2023	SELL	$30.85 - $93.17 $84,097 - $253,981	-2,726 Reduced 58.29%	1,951 $177,000
Q4 2022 Feb 14, 2023	BUY	$22.15 - $42.11 $85,233 - $162,039	3,848 Added 464.17%	4,677 $177,000
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $10,461 - $19,668	539 Added 185.86%	829 $20,000
Q2 2022 Aug 15, 2022	SELL	$20.71 - $36.5 $29,366 - $51,757	-1,418 Reduced 83.02%	290 $9,000
Q1 2022 May 16, 2022	SELL	$24.12 - $39.6 $93,995 - $154,321	-3,897 Reduced 69.53%	1,708 $56,000
Q4 2021 Feb 14, 2022	BUY	$25.61 - $110.96 $65,766 - $284,945	2,568 Added 84.56%	5,605 $148,000
Q3 2021 Nov 15, 2021	BUY	$100.0 - $143.02 $112,600 - $161,040	1,126 Added 58.92%	3,037 $305,000
Q2 2021 Aug 16, 2021	BUY	$78.27 - $151.29 $149,573 - $289,115	1,911 New	1,911 $271,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.